Astrazeneca Plc $AZN Shares Sold by Oxbow Advisors LLC

Oxbow Advisors LLC decreased its holdings in Astrazeneca Plc (NYSE:AZN) by 48.2% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 40,552 shares of the company’s stock after selling 37,736 shares during the quarter. Oxbow Advisors LLC’s holdings in Astrazeneca were worth $7,998,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in the business. Triumph Capital Management acquired a new stake in Astrazeneca during the 3rd quarter worth approximately $25,000. MV Capital Management Inc. purchased a new position in Astrazeneca in the 4th quarter valued at approximately $26,000. Bangor Savings Bank grew its stake in shares of Astrazeneca by 102.7% in the fourth quarter. Bangor Savings Bank now owns 304 shares of the company’s stock worth $28,000 after acquiring an additional 154 shares in the last quarter. Eagle Bay Advisors LLC acquired a new position in shares of Astrazeneca in the fourth quarter worth $30,000. Finally, YANKCOM Partnership purchased a new stake in shares of Astrazeneca during the fourth quarter worth $31,000. Institutional investors and hedge funds own 20.35% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on AZN shares. Weiss Ratings cut Astrazeneca from a “buy (b)” rating to a “buy (b-)” rating in a research note on Thursday, June 18th. Wall Street Zen raised Astrazeneca from a “hold” rating to a “buy” rating in a research note on Saturday, May 2nd. DZ Bank upgraded Astrazeneca from a “neutral” rating to a “buy” rating in a report on Wednesday, April 29th. TD Cowen reaffirmed a “buy” rating on shares of Astrazeneca in a research report on Wednesday, March 18th. Finally, Jefferies Financial Group reiterated a “buy” rating on shares of Astrazeneca in a research note on Friday, June 26th. Fourteen investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, Astrazeneca currently has an average rating of “Moderate Buy” and an average target price of $205.33.

Astrazeneca Price Performance

Astrazeneca stock opened at $194.96 on Friday. The company has a current ratio of 0.91, a quick ratio of 0.71 and a debt-to-equity ratio of 0.52. The company has a fifty day simple moving average of $183.96 and a 200-day simple moving average of $187.95. The stock has a market cap of $302.36 billion, a P/E ratio of 29.27, a price-to-earnings-growth ratio of 1.58 and a beta of 0.24. Astrazeneca Plc has a 12-month low of $137.23 and a 12-month high of $212.71.

Astrazeneca (NYSE:AZN) last posted its earnings results on Wednesday, April 29th. The company reported $2.58 EPS for the quarter, beating the consensus estimate of $2.52 by $0.06. Astrazeneca had a return on equity of 30.86% and a net margin of 17.19%.The firm had revenue of $15.29 billion for the quarter, compared to analyst estimates of $14.93 billion. Equities analysts expect that Astrazeneca Plc will post 10.28 EPS for the current fiscal year.

Astrazeneca Company Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.